ArticleMedicine2025
Aripiprazole for treatment of attenuated psychosis syndrome in an adolescent with 22q11.21 deletion syndrome: A case report.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleThe 22q11.2 deletion syndrome is a prevalent genetic condition associated with an increased risk of psychotic disorders. This case report describes an adolescent girl diagnosed with 22q11.2 deletion syndrome at the age of 4 years. She had a history of developmental delays, hearing impairments, and orthopedic complications requiring multiple surgeries. PATIENT CONCERNS: At 15 years of age, she had a 2-month history of abnormal beliefs, perceptual disturbances, behavioral changes, and irritability. DIAGNOSES: She was diagnosed with attenuated psychosis syndrome.
interventionsShe was treated with aripiprazole as a therapeutic intervention coupled with cognitive behavioral therapy, leading to a significant improvement in her symptoms; however, she developed akathisia and was therefore switched to risperidone, which was better tolerated in the long run. OUTCOMES: This case emphasizes the need for early intervention and personalized, tailored treatment options that can address the unique needs and vulnerabilities of these patients with complex genetic conditions and associated psychiatric manifestations. LESSONS: This case report represents the therapeutic success achieved with aripiprazole, demonstrating the potential effectiveness of this medication and its potential to improve patient outcomes when it is coupled with cognitive behavioral therapy, highlights the vulnerability of the patient group to antipsychotic-related side effects, and underscores the need for further development of optimized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.